Mobile

A clinical trial in patients with moderate to severe plaque psoriasis comparing the efficacy and safety of taking a drug called Ixekizumab either every 4 weeks or every 2 weeks

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-000190-12

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the efficacy of continuous every 2-week (Q2W) dosing versus continuous every 4-week (Q4W) dosing of ixekizumab in the treatment of patients with moderate-to-severe plaque psoriasis (Ps), as measured by static Physician Global Assessment (sPGA) (0,1) and PASI 75 (75% improvement from baseline in the Psoriasis Area and Severity Index).

Critère d'inclusion

  • Moderate to Severe Plaque Psoriasis

Liens